Trial Profile
The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Adverse reactions
- Sponsors Alexion Pharmaceuticals
- 09 Mar 2017 Status changed from recruiting to completed.
- 01 May 2015 New trial record